Abstract
We aimed to summarise recent advances in the therapy of diabetic neuropathy. Although all therapeutic choices in the treatment of diabetes mellitus itself are based on clear pathophysiological basis, this approach is less present in the treatment of the “forgotten complication”, diabetic neuropathy. As part of pathogenetic oriented treatment, the role of glycemic control and cardiovascular risk factors are reviewed. The mode of action of benfotiamine is based on inhibition of key alternative pathways, including the polyol, hexosamine, protein-kinase-C pathways, and inhibition of advanced glycation end products formation, just as on activation of transketolase. Alpha- lipoic-acid is considered as the most potent antioxidant. Other forms of pathogenetic oriented treatment, including actovegin, will be summarised. The anticonvulsants gabapentin and pregabalin, as well as the antidepressant duloxetine represent the most important new drugs among agents for symptomatic relief. Most likely, we should offer combination treatment to our patients much more often, first of all combination of pathogenetic and symptomatic drugs. Finally, the broad spectrum of non-pharmacological treatment will be reviewed.
Keywords: Diabetic neuropathy, benfotiamine, alpha-lipoic-acid, gabapentin, pregabalin, duloxetine.
Current Pharmaceutical Design
Title:Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Volume: 19 Issue: 27
Author(s): Tamas Varkonyi, Zsuzsanna Putz, Katalin Keresztes, Timea Martos, Csaba Lengyel, Alin Stirban, Gyorgy Jermendy and Peter Kempler
Affiliation:
Keywords: Diabetic neuropathy, benfotiamine, alpha-lipoic-acid, gabapentin, pregabalin, duloxetine.
Abstract: We aimed to summarise recent advances in the therapy of diabetic neuropathy. Although all therapeutic choices in the treatment of diabetes mellitus itself are based on clear pathophysiological basis, this approach is less present in the treatment of the “forgotten complication”, diabetic neuropathy. As part of pathogenetic oriented treatment, the role of glycemic control and cardiovascular risk factors are reviewed. The mode of action of benfotiamine is based on inhibition of key alternative pathways, including the polyol, hexosamine, protein-kinase-C pathways, and inhibition of advanced glycation end products formation, just as on activation of transketolase. Alpha- lipoic-acid is considered as the most potent antioxidant. Other forms of pathogenetic oriented treatment, including actovegin, will be summarised. The anticonvulsants gabapentin and pregabalin, as well as the antidepressant duloxetine represent the most important new drugs among agents for symptomatic relief. Most likely, we should offer combination treatment to our patients much more often, first of all combination of pathogenetic and symptomatic drugs. Finally, the broad spectrum of non-pharmacological treatment will be reviewed.
Export Options
About this article
Cite this article as:
Varkonyi Tamas, Putz Zsuzsanna, Keresztes Katalin, Martos Timea, Lengyel Csaba, Stirban Alin, Jermendy Gyorgy and Kempler Peter, Current Options and Perspectives in the Treatment of Diabetic Neuropathy, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/13816128113199990310
DOI https://dx.doi.org/10.2174/13816128113199990310 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design GABA Puts a Stop to Pain
Current Drug Targets - CNS & Neurological Disorders Metabolic Effects of Metformin in Humans
Current Diabetes Reviews Intermittent Transient Motor Aphasia Associated with Acute Lithium Toxicity: A Case Report and Brief Review
Current Drug Safety Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Voltage-Gated Sodium Channels: Mutations, Channelopathies and Targets
Current Medicinal Chemistry The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews Techniques to Investigate Neuronal Mitochondrial Function and its Pharmacological Modulation
Current Drug Targets Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?
Current Molecular Medicine A Hybrid PSO-DEFS Based Feature Selection for the Identification of Diabetic Retinopathy
Current Diabetes Reviews A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Synthesis, Antidiabetic and Hypolipidemic Activities of New Diethylamine and Triethoxysilyl Derivatives of Tolbutamide on Rats
Medicinal Chemistry Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry Pharmacogenetic Applications of the Post Genomic Era
Current Pharmaceutical Biotechnology High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews